Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries.
about
Factors influencing clinical trial site selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study)Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agendaActors involved in the regulation of clinical research: comparison of Finland to England, Canada, and the USA.Early results from a multi-component French public-private partnership initiative to improve participation in clinical research - CeNGEPS: a prospective before-after studyA pilot test of the new Swiss regulatory procedure for categorizing clinical trials by risk: A randomized controlled trial.Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study.Clinical research in Finland in 2002 and 2007: quantity and type.Clinical drug trials in general practice: a 10-year overview of protocols.Barriers to the conduct of randomised clinical trials within all disease areas.Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities.The GCP guideline and its interpretation - perceptions of clinical trial teams in sub-Saharan Africa.An ESMO-EORTC position paper on the EU clinical trials regulation and EMA's transparency policy: making European research more competitive again.Non-Commercial versus Commercial Clinical Trials: a Retrospective Study of the Applications Submitted to a Research Ethics Committee.New European Clinical Trial Regulation: perception and expectations in Italy.The law of unintended consequences.Europe proposes revision of clinical-trial rules
P2860
Q30557355-6B1530B2-063C-435E-8C5C-F5AE312A9D8FQ34851245-C07E1E39-5C25-48D1-8551-C020C1B4BFACQ35343105-05C30FC8-35F5-44D3-A178-F03736BD0C2CQ35749448-2FA459E7-09E0-489A-A40C-4C4F93D72765Q36288020-8CD231F3-77FB-4510-A95C-7121006839AEQ36302796-DBE4E9AD-7423-4D7A-B12C-56FC897EBD27Q36858896-DED04DD6-0E98-47BE-BB4E-FDC2676FAFDEQ36901340-83FE00C6-41C7-4229-818F-7EE64A4649D3Q38369293-025DA12D-0E2B-4131-B5D7-42E2B3CB1B4DQ38683404-DC605C74-038B-4BE3-B25B-DEDB41BA94F3Q39562749-5E589E7C-1305-4883-BCCA-E9975D4C41EFQ48044596-4949F9F3-B8F6-4072-AD3D-EE2480914DC4Q49984786-DF3E1D08-C06E-40F1-B493-A0A5041D0093Q50756656-E482D2D0-6138-42B3-83C2-40A62036019BQ55653529-1DE011B4-F3EB-47E5-A56D-66FC47A27C9DQ74437365-7F64B008-8913-4031-83FD-D7281C337811
P2860
Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Impact assessment of the Europ ...... agencies in six EU countries.
@ast
Impact assessment of the Europ ...... agencies in six EU countries.
@en
type
label
Impact assessment of the Europ ...... agencies in six EU countries.
@ast
Impact assessment of the Europ ...... agencies in six EU countries.
@en
prefLabel
Impact assessment of the Europ ...... agencies in six EU countries.
@ast
Impact assessment of the Europ ...... agencies in six EU countries.
@en
P2860
P356
P1433
P1476
Impact assessment of the Europ ...... agencies in six EU countries.
@en
P2093
Markus Hartmann
P2860
P2888
P356
10.1186/1745-6215-13-53
P577
2012-04-29T00:00:00Z
P5875
P6179
1028810140